GW Pharmaceuticals plc (GWPH) was a big mover last session with its shares rising just over 13% on the day. The upside was owing to the company’s announcement that the American Academy of Neurology (AAN) has released data from physician-led FDA authorized Epidiolex “expanded access” programs for children and young adults with treatment-resistant epilepsy who have exhausted available treatment options. This development led to far more shares changing hands yesterday than in a normal session. This breaks the recent trend of the company as the stock is now trading above the past one month’s volatile price range of $86.46 to $100.48.

GW Pharmaceuticals currently holds a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.